Atezolizumab for the treatment of colorectal cancer: the latest evidence and clinical potential

References

• Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin. 2017 May 06;67(3):177–193. PubMed PMID: 28248415; eng.
   PubMed Web of Science ®Google Scholar
• [cited 2017 Sep 29]. Available from: https://bowel-cancer.canceraustralia.gov.au/statistics.
   Google Scholar
• Venook AP, Niedzwiecki D, Lenz H-J, et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol. 2014;32(18_suppl):LBA3–LBA3. PubMed PMID: 28141983.
   Web of Science ®Google Scholar
• Heinemann V, Von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065–1075. DOI:10.1016/S1470-2045(14)70330-4.
   PubMed Web of Science ®Google Scholar
• Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015 Oct;16(13):1306–1315. PubMed PMID: 26338525; eng.
   PubMed Web of Science ®Google Scholar
• Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer?. BMC Med. 2016 May 05;14(1):73.
   PubMed Web of Science ®Google Scholar
• Calles A, Liao X, Sholl LM, et al. Expression of PD-1 and its ligands, PD-L1 and PD-L2, in smokers and never smokers with <em>KRAS</em>-mutant lung cancer. J Thorac Oncol. 10(12):1726–1735. DOI: 10.1097/JTO.0000000000000687.
   PubMed Web of Science ®Google Scholar
• Tan S, Liu K, Chai Y, et al. Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab. Protein Cell. 2017 May 09. DOI:10.1007/s13238-017-0412-8.
   Web of Science ®Google Scholar
• Hodi FS, Chesney J, Pavlick AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol. 2016 Nov;17(11):1558–1568. PubMed PMID: 27622997; PubMed Central PMCID: PMCPMC5630525. eng.
   PubMed Web of Science ®Google Scholar
• Borghaei H, Brahmer J, Horn L, et al. P2.35: nivolumab vs docetaxel in advanced NSCLC: checkMate 017/057 2-Y update and exploratory cytokine profile analysis: track: immunotherapy. J Thorac Oncol. 2016 Oct;11(10s):S237–S238. PubMed PMID: 27676569; eng.
   PubMedGoogle Scholar
• Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. New England J Med. 2015;373(19):1803–1813. PubMed PMID: 26406148.
   PubMed Web of Science ®Google Scholar
• Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017 Mar;18(3):312–322. PubMed PMID: 28131785; eng.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 Blockade with nivolumab in relapsed or refractory Hodgkin’s Lymphoma. New England J Med. 2015;372(4):311–319. PubMed PMID: 25482239.
   PubMed Web of Science ®Google Scholar
• Pillai RN, Behera M, Owonikoko TK, et al. Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: a systematic analysis of the literature. Cancer. 2017 Sep 28 PubMed PMID: 28960263; eng. DOI:10.1002/cncr.31043.
   Google Scholar
• O’Donnell JS, Long GV, Scolyer RA, et al. Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treat Rev. 2017 Jan 01;52(Supplement C):71–81.
   PubMedGoogle Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. New England J Med. 2015;372(26):2509–2520. PubMed PMID: 26028255.
   PubMed Web of Science ®Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, et al. Signatures of mutational processes in human cancer. Nature. 2013 Aug 22;500(7463):415–421. PubMed PMID: 23945592; PubMed Central PMCID: PMCPMC3776390. eng.
   PubMed Web of Science ®Google Scholar
• Schwitalle Y, Kloor M, Eiermann S, et al. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology. 2008 Apr;134(4):988–997. PubMed PMID: 18395080; eng.
   PubMed Web of Science ®Google Scholar
• Pawlik TM, Raut CP, Rodriguez-Bigas MA. Colorectal carcinogenesis: MSI-H versus MSI-L. Dis Markers. 2004;20(4–5): 199–206. PubMed PMID: 15528785; PubMed Central PMCID: PMCPMC3839332. eng.
   PubMed Web of Science ®Google Scholar
• Koopman M, Kortman GA, Mekenkamp L, et al. Deficient mismatch repair system in patients with sporadic advanced colorectal cancer. Br J Cancer. 2009 Jan 27;100(2):266–273. PubMed PMID: 19165197; PubMed Central PMCID: PMCPMC2634718. eng.
   PubMed Web of Science ®Google Scholar
• Basile D, Garattini SK, Bonotto M, et al. Immunotherapy for colorectal cancer: where are we heading? Expert Opin Biol Ther. 2017 Jun;17(6):709–721. PubMed PMID: 28375039; eng.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013 Jul 25;39(1):1–10. PubMed PMID: 23890059; eng.
   PubMed Web of Science ®Google Scholar
• Deng R, Bumbaca D, Pastuskovas CV, et al. Preclinical pharmacokinetics, pharmacodynamics, tissue distribution, and tumor penetration of anti-PD-L1 monoclonal antibody, an immune checkpoint inhibitor. mAbs. 2016;8(3):593–603. PubMed PMID: 26918260; PubMed Central PMCID: PMCPMC4966836. eng.
   PubMed Web of Science ®Google Scholar
• Patel R, Bock M, Polotti CF, et al. Pharmacokinetic drug evaluation of atezolizumab for the treatment of locally advanced or metastatic urothelial carcinoma. Expert Opin Drug Metab Toxicol. 2017 Feb 01;13(2):225–232.
   PubMed Web of Science ®Google Scholar
• Stroh M, Winter H, Marchand M, et al. Clinical pharmacokinetics and pharmacodynamics of atezolizumab in metastatic urothelial carcinoma. Clin Pharmacol Ther. 2017;102(2):305–312.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014 Nov 27;515(7528):563–567. PubMed PMID: 25428504; PubMed Central PMCID: PMCPMC4836193.
   PubMed Web of Science ®Google Scholar
• [cited 2017 Sep 29]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/761041lbl.pdf.
   Google Scholar
• A study of atezolizumab administered in combination with bevacizumab and/or with chemotherapy in participants with locally advanced or metastatic solid tumors. [cited 2017 Sep 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT01633970.
   Google Scholar
• Bendell JC, Powderly JD, Lieu CH, et al. Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol. 2015;33(3_suppl):704.
   Google Scholar
• Wallin J, Pishvaian MJ, Hernandez G, et al. Abstract 2651: clinical activity and immune correlates from a phase Ib study evaluating atezolizumab (anti-PDL1) in combination with FOLFOX and bevacizumab (anti-VEGF) in metastatic colorectal carcinoma. Cancer Res. 2016;76(14 Supplement):2651.
   Google Scholar
• Hochster HS, Bendell JC, Cleary JM, et al. Efficacy and safety of atezolizumab (atezo) and bevacizumab (bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC). J Clin Oncol. 2017;35(4_suppl):673.
   Web of Science ®Google Scholar
• Bendell JCE. A phase Ib study of safety and clinical activity of atezolizumab (A) and cobimetinib (C) in patients (pts) with metastatic colorectal cancer (mCRC). J Clin Oncol. 2018;36(suppl 4S; abstr 560).
   Google Scholar
• A study of RO6958688 in participants with locally advanced and/or metastatic carcinoembryonic antigen positive solid tumors. [cited 2017 Sep 18]. Available from: https://clinicaltrials.gov/ct2/show/NCT02324257.
   Google Scholar
• Bacac M, Klein C, Umana P. CEA TCB: a novel head-to-tail 2:1 T cell bispecific antibody for treatment of CEA-positive solid tumors. Oncoimmunology. 2016 Jun 24.
   Web of Science ®Google Scholar
• Tabernero J, Melero I, Ros W, et al. Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC). J Clin Oncol. 2017;35(15_suppl):3002.
   PubMedGoogle Scholar
• McDermott J, Jimeno A. Pembrolizumab: PD-1 inhibition as a therapeutic strategy in cancer. Drugs Today (Barcelona, Spain: 1998). 2015 Jan;51(1):7–20. PubMed PMID: 25685857; eng.
   PubMed Web of Science ®Google Scholar
• Diaz LA, Marabelle A, Delord J-P, et al. Pembrolizumab therapy for microsatellite instability high (MSI-H) colorectal cancer (CRC) and non-CRC. J Clin Oncol. 2017;35(15_suppl):3071.
   Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015 May 30;372(26):2509–2520. PubMed PMID: PMC4481136.
   PubMed Web of Science ®Google Scholar
• Nanda R, Chow LQ, Dees EC, et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J Clin Oncol: off J Am Soc Clin Oncol. 2016 Jul 20;34(21):2460–2467. PubMed PMID: 27138582; eng.
   PubMed Web of Science ®Google Scholar
• Plimack ER, Bellmunt J, Gupta S, et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): a non-randomised, open-label, phase 1b study. Lancet Oncol. 2017 Feb;18(2):212–220. PubMed PMID: 28081914; eng.
   PubMed Web of Science ®Google Scholar
• Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016 Jun;17(6):717–726. PubMed PMID: 27157491; eng.
   PubMed Web of Science ®Google Scholar
• Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017 Sep;18(9):1182–1191. PubMed PMID: 28734759; eng.
   PubMed Web of Science ®Google Scholar
• Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018 Jan 20:JCO2017769901. PubMed PMID: 29355075. DOI:10.1200/JCO.2017.76.9901.
   PubMedGoogle Scholar
• Chung KY, Gore I, Fong L, et al. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. J Clin Oncol: off J Am Soc Clin Oncol. 2010 Jul 20;28(21):3485–3490. PubMed PMID: 20498386; eng.
   PubMed Web of Science ®Google Scholar
• Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. New England J Med. 2012;366(26):2443–2454. PubMed PMID: 22658127.
   PubMed Web of Science ®Google Scholar
• Klingbiel D, Saridaki Z, Roth AD, et al. Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. Ann Oncol. 2015 Jan;26(1):126–132. PubMed PMID: 25361982.
   PubMed Web of Science ®Google Scholar
• Luen SJ, Savas P, Fox SB, et al. Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. Pathology. 2017 Feb;49(2):141–155. PubMed PMID: 28049579.
   PubMed Web of Science ®Google Scholar
• Guinney J, Dienstmann R, Wang X, et al. The consensus molecular subtypes of colorectal cancer. Nat Med. 2015 Nov;21(11):1350–1356. PubMed PMID: 26457759; PubMed Central PMCID: PMCPMC4636487.
   PubMed Web of Science ®Google Scholar